EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)‐rearranged acute leukaemia

Yoana Arroyo-Berdugo, Antonella Di Mambro, Volker Behrends, Michelle A Sahai, Luca Cozzuto, Immacolata Zollo, Julia Ponomarenko, Owen Williams, John Gribben, Yolanda Calle, Bela Patel, Maria Teresa Esposito iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Yoana Arroyo-Berdugo und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Life and Health Sciences, University of Roehampton, London, UK. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Protein Phosphatase 2, Leukemia, Myeloid, Acute, Colforsin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leukaemia UK, University of Roehampton, University of Surrey.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Activation of Protein Phosphatase 2A (PP2A), via genetic and pharmacologic modulation of SET, has recently being identified as a promising strategy to therapeutically target acute myeloid leukaemia (AML) carrying KMT2A (MLL) chromosomal translocations ( KMT2A ‐r AML). Experimental Approach In this study, we investigated the expression of PP2A subunits and the therapeutic potential of forskolin, a cyclic adenosine monophosphate (cAMP) elevating natural compound that has been reported as a PP2A activator. Key Results Our data show that PPP2CA encoding protein phosphatase 2 catalytic subunit α is abundantly expressed in KMT2A ‐r AML cells. Treatment with forskolin arrests proliferation; induces cell death; represses the expression of MYC , HOXA9 and HOXA10 ; stimulates PP2A activity; and attenuates the activity of ERK1/2 in KMT2A ‐r AML cells. Forskolin increases sensitivity to standard‐of‐care daunorubicin in KMT2A ‐AML cell lines and PDX. Silencing PPP2CA partially rescues the cytotoxic effect of forskolin, stimulates ERK1/2, inhibits GSK3β, and abolishes the forskolin‐mediated repression of c‐ MYC and HOXA10, but it did not affect the potentiation of response to daunorubicin. This effect was also not dependent on increase of cAMP, but it was because of increase in the intracellular accumulation of daunorubicin, through inhibition of drug efflux pump P‐glycoprotein 1 (multidrug resistance protein). Conclusions and Implications In conclusion, our findings highlight a novel mechanism of action for forskolin and support a potential role of this natural compound in combination with current conventional agent daunorubicin in the treatment of KMT2A ‐r AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Lymphoid Leukemia ProteinProtein Phosphatase 2Leukemia, Myeloid, AcuteColforsinHistone-Lysine N-MethyltransferaseAntineoplastic AgentsHumansCell Line, TumorCell ProliferationAnimalsMiceGene RearrangementDaunorubicin

Stichwörter der Autor:innen

AMLERK1/2GSK3βHOXAKMT2AMDRMLLMYCPP2AP‐glycoproteindaunorubicinforskolinleukaemianatural compoundsphosphatase

Substanzen

Myeloid-Lymphoid Leukemia ProteinKMT2A protein, humanProtein Phosphatase 2ColforsinHistone-Lysine N-MethyltransferaseDaunorubicinAntineoplastic Agents

Autor:innen und Institutionen

  • School of Life and Health Sciences, University of Roehampton, London, UK.
  • School of Biomedical Sciences, University of West London, London, UK.
  • Division of Biosciences, Department of Life Sciences, College of Health and Life Sciences, Brunel University of London, Uxbridge, UK.
  • Centre Genomic Regulation, CRG, Barcelona, Spain.
  • CEINGE Biotecnologie Avanzate, Naples, Italy.
  • University Pompeu Fabra (UPF), Barcelona, Spain.

ORCID-Profile: Maria Teresa Esposito

Förderung

  • Leukaemia UK
  • University of Roehampton
  • University of Surrey
  • Institute of Biomedical Science

Zitieren

APA

Arroyo-Berdugo, Y., Di Mambro, A., Behrends, V., Sahai, M. A., Cozzuto, L., Zollo, I., Ponomarenko, J., Williams, O., Gribben, J., Calle, Y., Patel, B., & Esposito, M. T. (2025). Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)‐rearranged acute leukaemia. British Journal of Pharmacology. https://doi.org/10.1111/bph.70158

Vancouver

Arroyo-Berdugo Y, Di Mambro A, Behrends V, Sahai MA, Cozzuto L, Zollo I, et al. Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)‐rearranged acute leukaemia. British Journal of Pharmacology. 2025. doi:10.1111/bph.70158

BibTeX
@article{ArroyoBerdugo2025,
  author = {Arroyo-Berdugo, Yoana and Di Mambro, Antonella and Behrends, Volker and Sahai, Michelle A and Cozzuto, Luca and Zollo, Immacolata and Ponomarenko, Julia and Williams, Owen and Gribben, John and Calle, Yolanda and Patel, Bela and Esposito, Maria Teresa},
  title = {Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)‐rearranged acute leukaemia},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70158}
}
Kostenlos starten →